Immunotherapy as a therapeutic treatment for neurodegenerative disorders

Journal of Neurochemistry

Volumn 87, Issue 4, 2003, Pages 801-808

  White, Anthony R ^b   Hawke, Simon H ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

Central nervous system; Immunization; Neurodegeneration; Therapy; Vaccine

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; GLATIRAMER;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; HUMAN; HUNTINGTON CHOREA; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOTHERAPY; MOLECULAR CLONING; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; PROTEIN FOLDING; SHORT SURVEY; SYMPTOMATOLOGY;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; MICE; NEURODEGENERATIVE DISEASES; PRION DISEASES; PRIONS; SENILE PLAQUES;

MUS MUSCULUS;

EID: 0344824700     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.02064.x     Document Type: Short Survey

References (56)

1. Bacskai B. J., Kajdasz S. T., Christie R. H., Carter C., Games D., Seubert P., Schenk D. and Hyman B. T. (2001) Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7, 369-372.
2. Bacskai B. J., Kajdasz S. T., McLellan M. E., Games D., Seubert P., Schenk D. and Hyman B. T. (2002) Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J. Neurosci. 22, 7873-7878.
3. Bard F., Cannon C., Barbour R. et al. (2000) Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916-919.
4. Bard F., Barbour R., Cannon C. et al. (2003) Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl Acad. Sci. USA 100, 2023-2028.
5. Borchelt D. R., Scott M., Taraboulos A., Stahl N. and Prusiner S. B. (1990) Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells. J. Cell. Biol. 110, 743-752.
6. Bush A. I. (2000) Metals and neuroscience. Curr. Opin. Chem. Biol. 4, 184-191.
7. Das P., Murphy M. P., Younkin L. H., Younkin S. G. and Golde T. E. (2001) Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging 22, 721-727.
8. DeMattos R. B., Bales K. R., Cummins D. J., Dodart J.-C., Paul S. M. and Holtzman D. M. (2001) Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 98, 8850-8855.
9. Dodart J.-C., Bales K. R., Gannon K. S. et al. (2002) Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nature Neurosci. 5, 452-457.
10. Enari M., Flechsig E. and Weissmann C. (2001) Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc. Natl Acad. Sci. USA 98, 9295-9299.
11. Esiri M. M. (2001) Is an effective immune intervention for Alzheimer's disease in prospect? TIPS 22, 2-3.
12. Frenkel D., Balass M. and Solomon B. (1998) N-terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies. J. Neuroimmunol. 88, 85-90.
13. Frenkel D., Solomon B. and Benhar I. (2000) Modulation of Alzheimer's β-amyloid neurotoxicity by site-directed single-chain antibody. J. Neuroimmunol. 106, 23-31.
14. Gabizon R., McKinley M. P., Groth D. and Prusiner S. B. (1988) Immunoaffinity purification and neutralization of scrapie prion infectivity. Proc. Natl Acad. Sci. USA 85, 6617-6621.
15. Sc propagation in prion-infected cells. J. Biol. Chem. 278, 18524-18531.
16. Gura T. (2002) Magic bullets hit the target. Nature 417, 584-586.
17. Hasnain S. S., Murphy L. M., Strange R. W., Grossmann J. G., Clarke A. R., Jackson G. S. and Collinge J. (2001) XAFS study of the high-affinity copper-binding site of human PrP (91-231) and its low-resolution structure in solution. J. Mol. Biol. 311, 467-473.
18. Hawke S., Matsuo H., Nicolle M., Malcherek G., Melms A. and Willcox N. (1996) Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargeting. Immunol. Today 17, 307-311.
19. Heppner F. L., Arrighi I., Kalinke U. and Aguzzi A. (2001a) Immunity against prions? TIMM 7, 477-479.
20. Heppner F. L., Musahl C., Arrighi I., Klein M. A., Rülicke T., Oesch B., Zinkemagel R. M., Kalinke U. and Aguzzi A. (2001b) Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294, 178-182.
21. Hock C., Konietzko U., Papassotiropoulos A., Wollmer A., Streffer J., von Rotz R. C., Davey G., Moritz E. and Nitsch R. M. (2002) Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease. Nat. Med. 8, 1270-1275.
22. Hock C., Konietzko U., Streffer J. R. et al. (2003) Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547-554.
23. Horiuchi M. and Caughey B. (1999) Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J. 18, 3193-3203.
24. Ingram D. K. (2001) Vaccine development for Alzheimer's disease: a shot of good news. TINS 24, 305-307.
25. Jackson G. S., Hosszu L. L., Power A., Hill A. F., Kenney J., Saibil H., Craven C. J., Waltho J. P., Clarke A. R. and Collinge J. (1999) Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. Science 283, 1935-1937.
26. Jackson G. S., Murray I., Hosszu L. L., Gibbs N., Waltho J. P., Clarke A. R. and Collinge J. (2001) Location and properties of metal-binding sites on the human prion protein. Proc. Natl Acad. Sci. USA 98, 8531-8535.
27. Janus C., Pearson J., McLaurin J. et al. (2000) Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982.
28. Kipnis J., Yoles E., Porat Z., Cohen A., Mor F., Sela M., Cohen I. R. and Schwartz M. (2000) T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc. Natl Acad. Sci. USA 97, 7446-7451.
29. Lecerf J.-M., Shirley T. L., Zhu Q., Kazantsev A., Amersdorfer P., Housman D. E., Messer A. and Huston J. S. (2001) Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc. Natl Acad. Sci. USA 98, 4764-4769.
30. Lee V. M.-Y. (2001) Aβ immunization: moving Aβ peptide from brain to blood. Proc. Natl Acad. Sci. USA 98, 8931-8932.
31. Lue L. F., Kuo Y. M., Roher A. E., Brachova L., Shen Y., Sue L., Beach T., Kurth J. H., Rydel R. E. and Rogers J. (1999) Soluble amyloid β-peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853-862.
32. McLaurin J., Cecal R., Kierstead M. E. et al. (2002) Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 8, 1263-1269.
33. McLean C. A., Chemy R. A., Fraser F. W., Fuller S. J., Smith M. J., Beyreuther K., Bush A. I. and Masters C. L. (1999) Soluble pool of A β amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860-866.
34. Morgan D., Diamond D. M., Gottschall P. E. et al. (2000) Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985.
35. Nicoll J. A. R., Wilkinson D., Holmes C., Steart P., Markham H. and Weller R. (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nature Med. 9, 448-452.
36. Peretz D., Williamson R. A., Kaneko K. et al. (2001) Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412, 739-743.
37. Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Stanfenbiel M., Mathews P. M. and Jucker M. (2002) Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science 298, 1379.
38. Prusiner S. B., Groth D., Serban A., Koehler R., Foster D., Torchia M., Burton D., Yang S. L. and DeArmond S. J. (1993) Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc. Natl Acad. Sci. USA 90, 10608-10612.
39. Schenk D. (2002) Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 3, 824-828.
40. Schenk D., Barbour R., Dunn W. et al. (1999) Immunization with amyloid-β attenuates Alzheimer-disease like pathology in the PDAPP mouse. Nature 400, 173-177.
41. Sela M., Arnon R. and Schechter B. (2002) Therapeutic vaccines realities of today and hopes for the future. Drug Disc. Today 7, 664-673.
42. Sercarz E. (2002) Processing creates the self. Nature Immunol. 3, 110-112.
43. Sethi S., Lipford G., Wagner H. and Kretzschmar H. (2002) Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet 360, 229-230.
44. Sigurdsson E. M., Brown D. R. Daniels M., Kascsak R. J., Kascsak R., Carp R. Meeker H. C., Frangione B. and Wisniewski T. (2002) Immunization delays the onset of prion disease in mice. Am. J. Pathol. 161, 13-17.
45. Solomon B. (2001) Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease. DNA Cell Biol. 20, 697-703.
46. Solomon B., Koppel R., Hanan E. and Katzav T. (1996) Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Neurobiology 93, 452-455.
47. Souan L., Margalit R., Brenner O., Cohen I. R. and Mor F. (2001a) Self prion protein peptides are immunogenic in Lewis rats. J. Autoimmun. 17, 303-310.
48. Souan L., Yuval T., Felling Y., Cohen I. R., Taraboulos A. and Mor F. (2001b) Modulation of proteinase-K resistant prion protein by prion peptide immunization. Eur. J. Immunol. 31, 2338-2346.
49. Steinman L. (1995) Escape from 'horror autotoxicus': pathogenesis and treatment of autoimmune disease. Cell 80, 7-10.
50. Stevenson P. G., Bangham C. R. and Hawke S. (1997a) Recruitment, activation and proliferation of CD8+ memory T cells in an immunoprivileged site. Eur. J. Immunol. 27, 3259-3268.
51. Stevenson P. G., Hawke S., Sloan D. J. and Bangham C. R. (1997b) The immunogenicity of intracerebral virus infection depends on anatomical site. J. Virol. 71, 145-151.
52. Tal Y., Souan L., Cohen I. R., Meiner Z., Taraboulos A. and Mor F. (2002) Complete Freund's adjuvant immunization prolongs survival in experimental prion disease in mice. J. Neurosci. Res. 71, 286-290.
53. Ugen K. E. and Morgan D. (2001) Alzheimer's disease: molecularly based immunotherapeutics. DNA Cell Biol. 20, 677-678.
54. Westaway D. and Carlson G. A. (2002) Mammalian prion proteins: enigma, variation and vaccination. TIBS 27, 301-307.
55. White A. R., Enever P., Tayebi M., Mushens R., Linehan J., Brandner S., Anstee D., Collinge J. and Hawke S. (2003) Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422, 80-83.
56. Wilcock D. M., DiCarlo G., Henderson D., Jackson J., Clarke K., Ugen K. E., Gordon M. N. and Morgan D. (2003) Intracranially administered anti-Aβ antibodies reduce β-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 23, 3745-3751.